P1594 - Patients with Enteropathy-Associated T-Cell Lymphoma in the United States from 2000 to 2018: SEER Database Analysis

Rehmat Ullah Awan, MD¹, Ahmed Awad, MBBCh², Sophia Haroon Dar, MD³, Ambreen Nabeel, MBBS¹, Hrishikesh Samant, MD⁴, Ayokunle T.. Abegunde, MD^5
1Ochsner Rush Medical Center, Meridian, MS; ²Ain-Shams University, Cairo, Al Qahirah, Egypt; ³Northshore-Long Island Jewish Medical Center, New York, NY; ⁴Ochsner Medical Center, New Orleans, LA; ⁵Loyola University Medical Center, Maywood, IL

Introduction: Enteropathy-Associated T-Cell Lymphoma (EATL) is a rare lymphoma of T-cell origin associated with celiac disease. There is limited evidence in the literature about the incidence and causes of death in patients with EATL. We analyzed the Surveillance, Epidemiology, and End Results (SEER) data base to determine the incidence, trends and causes of death of patients with EATL in the U.S from 2000 to 2018.

Methods: Retrospective cohort study using the Surveillance Epidemiology and End-Results (SEER-18) Database to study EATL. Baseline characteristics including sex, age, race, behavior, laterality, sequence, and primary site of the tumor extracted. Moreover, treatment options (surgery, radiotherapy, and chemotherapy), status of patients either alive, dead due to cancer itself or other non-cancerous causes with listing of those non-cancerous causes was retrieved. Sub-group analysis based on sex was also done. Multiple latency periods (< 2 year, 2-5, 6–10, 11-15, and more than 15 years) were analyzed following EATL diagnosis. Causes of death were identified according to the international WHO classification 10th Revision (ICD-10 codes).

Results: There were 259 EATL patients, majority were aged 70-74 years old (n=36, 13.9%), predominantly males 155 (59.8%), most common in whites, (76.4%, n= 198), EATL was the only primary tumor in 177 (68.3%) cases, most common site was small bowel at different sites 84 (32.4%) followed by jejunum specifically 57 (22%), majority went for surgical resection (69.9%, n= 181) followed by chemotherapy (47.5%, n=123), 217 (83.7%) died during follow-up in this study. Overall 5 year survival probability was poor (Figure-A), patients with checmotherapy did relatively better (Figure-B), predominant race was white, and survival probability was also better in whites (Figure-C).

Discussion: EATL is a rare entity, mostly seein in males, between 70-74 years, and mostly originated in the small bowel. With over 80% death in five-year follow up period, EATL patients showed better survival if they underwent chemotherapy and were of white race.



Disclosures:


Rehmat Ullah Awan, MD¹, Ahmed Awad, MBBCh², Sophia Haroon Dar, MD³, Ambreen Nabeel, MBBS¹, Hrishikesh Samant, MD⁴, Ayokunle T.. Abegunde, MD⁵. P1594 - Patients with Enteropathy-Associated T-Cell Lymphoma in the United States from 2000 to 2018: SEER Database Analysis, ACG 2023 Annual Scientific Meeting Abstracts. Vancouver, BC, Canada: American College of Gastroenterology.